Trials / Terminated
TerminatedNCT00986440
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Monotherapy treatment with CS-7017 to assess progression-free-survival (PFS) of subjects who achieved an objective response of Disease Control on first line therapy with Folinic acid (leucovorin), Fluorouracil (5-FU), Oxaliplatin (Eloxatin) known as FOLFOX; or Folinic acid (leucovorin), Fluorouracil (5-FU), irinotecan (Camptosar) known as FOLFIRI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-7017 | CS-7017 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-07-31
- Primary completion
- 2012-10-29
- Completion
- 2012-10-29
- First posted
- 2009-09-30
- Last updated
- 2020-11-05
- Results posted
- 2020-11-05
Locations
39 sites across 9 countries: Czechia, France, Germany, Italy, Poland, Russia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00986440. Inclusion in this directory is not an endorsement.